US 12,214,034 B2
Vaccines against HPV and HPV-related diseases
Sangkon Oh, Baltimore, MD (US); Sandra Zurawski, Midlothian, TX (US); and Gerard Zurawski, Midlothian, TX (US)
Assigned to BAYLOR RESEARCH INSTITUTE, Dallas, TX (US)
Filed by BAYLOR RESEARCH INSTITUTE, Dallas, TX (US)
Filed on Jun. 6, 2023, as Appl. No. 18/329,696.
Application 18/329,696 is a continuation of application No. 17/194,779, filed on Mar. 8, 2021, granted, now 11,717,567.
Application 17/194,779 is a continuation of application No. 16/397,214, filed on Apr. 29, 2019, granted, now 10,940,195, issued on Mar. 9, 2021.
Application 16/397,214 is a continuation of application No. 15/111,357, granted, now 10,286,058, issued on May 14, 2019, previously published as PCT/US2015/011236, filed on Jan. 13, 2015.
Claims priority of provisional application 62/002,718, filed on May 23, 2014.
Claims priority of provisional application 61/926,821, filed on Jan. 13, 2014.
Prior Publication US 2024/0033340 A1, Feb. 1, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/12 (2006.01); A61K 39/395 (2006.01); C07K 14/005 (2006.01); C07K 14/025 (2006.01); C07K 16/28 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 39/395 (2013.01); A61K 39/39541 (2013.01); A61K 39/3955 (2013.01); C07K 14/005 (2013.01); C07K 16/2878 (2013.01); C12N 7/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/53 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/585 (2013.01); A61K 2039/6056 (2013.01); A61K 2039/70 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2319/74 (2013.01); C07K 2319/91 (2013.01); C12N 2710/20034 (2013.01)] 17 Claims
 
1. One or more nucleic acids encoding a fusion protein comprising an anti-CD40antibody or fragment thereof, comprising at least three complementarity determining regions (CDRs) from each of a heavy and light chain of an anti-CD40 antibody, at least one peptide linker and at least one human papillomavirus (HPV) E6 antigen and at least one HPV E7 antigen, wherein the E6 and E7 antigens comprise an antigen with at least 90% sequence identity to SEQ ID NO: 1 and an antigen with at least 90% sequence identity to SEQ ID NO:2; and
wherein the fusion protein comprises an amino acid sequence that has at least 95% sequence identity to SEQ ID NO: 19.